February 15, 2018 / 8:54 PM / in 4 months

BRIEF-Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT

Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc:

* ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT

* ARROWHEAD PHARMA- U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO ARO-AAT FOR TREATMENT OF A RARE GENETIC LIVER DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below